Trial Profile
Phase II Trial of Pulse Dosing of Lapatinib in Combination With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly-Diagnosed Glioblastoma Multiforme
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 10 Jul 2023 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.
- 10 Jul 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.
- 09 Sep 2022 Planned End Date changed from 7 Dec 2023 to 30 Jun 2024.